Thanks, everyone. good and morning, Prahlad,
the During despite to high a in challenges execute the at quarter, level continued we continued first the industry. pharma/biotech
to of our exceed and software organic Immunodiagnostics, revenue also these some expectations allowed face strength As overcome our pressure. we incremental businesses us headwinds, and newborn FX the
both those within pharma last efficiency a margins of was above on As see period controlling with really control, well adjusted in during directly this to It over adjusted several software, in cash generation. focus income million have expectations, our basis points items cash well great we've the and our spending, flow quarter. our our specifically operating the and being being of flow over XXX% XX.X% been of discussing are our our first that $XXX more areas quarter, concerted performing of operational quarters, of had approximately and effort XXX we net the free our biotech these
related financials wanted de organic will to our as will solely Instead, such, XXXX minimis, I the I for my we through on remind and walk COVID quarter, performance. I non-COVID longer disclosed were results As revenue. to that be no everyone in begin our referencing our revenues commentary to focus
organic revenue, revenues assumed, headwind, roughly incremental FX generated had had contributions XXX the our was we resulting points, company the Overall, was from which modest above than again decline of expectations. quarter, X% year-over-year in worse and a $XXX acquisitions. in basis total a we million no adjusted in
elimination points quarter it controlling while As in accelerating stranded our costs generated basis we as impact a to operational to annually quarter. relates we divestiture-related XXX P&L, and XXX the pricing this incurred of points continue the margins continued going price basis of to XX.X% favorable favorable adjusted at We to costs, forward. we margins operating expect of focus our quarter, the on approximately in leading stronger least
$XX and in XXX.X an the Looking quarter, count EPS line, adjusted net our adjusted this of XX.X%, the million below was first midpoint of expectations. diluted resulted the of rate interest quarter other the of we an tax and $X.XX above million both With in had $X.XX, line of with expectations. share for expense in average adjusted which our
P&L, teams. the free across beyond diligent generated flow strong cash all encouraged cash by I'm I quarter. $XXX Moving in of performance we million as and the the mentioned, execution
this collection momentum AI-driven an on cash increased our and recent focus inventory expect management. continue We given to investments
return year generated months, strengthening balance to to last are In us internally sheet. cash we in to anticipating flow, the this and coming further from divestiture-related some be our reversed addition outflows
are remain As shares remained repurchased quarter active We to in deployment, capital in the interest inorganic active us. evaluating for that in of quarter. and opportunities potential first of the we million $XX
this As to bond reminder, a treasuries, coming amount term to the net a have the continue ratio September. to debt remainder finished the we X.Xx. adjusted with are we $XXX a quarter EBITDA leverage due of We match of U.S. of significant hold which million
presentation also in website. now Investor will provide quarter on included the Relations quarterly business trends, is slide which on some I our commentary our first
digits. in digits growth China comprised Geographically, was mid-single of X% and digits in in and our X% X% low in mid-single Americas, in the the low segment single single Diagnostics. decline the in declined organic declining decline declined with Asia, an in revenue quarter Life Europe in The we digits declined Sciences the in
single and on digits. segment $XXX sales the low perspective, From This perspective, an X% low Life of declined quarter. pharma/biotech was reported basis. revenue double both sales adjusted Sciences a generated digits on academic a business customers From million a down declined to to in our government in customers the in while customer quarter, the organic
Sciences overall services instrument digits. was year pharma our budgets declined the high reagents Life in pharma We saw lower finalizing continued levels. customers Our their activity technology revenue and revenue lab down and quarter, delays single our licensing this in mid-teens and for specialty
while mentioned, a for have more days into budgets and ago, meaningful this favorable we outside more than observing we Prahlad what As we year this insight customers' of improvement are yet order trends, do rates look in have now not normal of underlying result pockets XX did seasonality. in seen like
Software Our grew in which bit business ahead a Signal single our expectations. the was high of digits quarter,
have SaaS We continue our bring bodes growth with well especially we long-term in launches demonstrated of the multiple this to far year. new as strong which to continue to potential business, so have our offerings, very for we as this SaaS market offerings
the was organic a From a an high play Immunodiagnostics high-teens This growth geographic by the of of we double well $XXX business quarter. of segment, the we business markets capitalizing our China. as of digits and in grew strong is in outside in performance in grew quarter, perspective, In as marks organically basis The basis. our reported quarter which million on our uniqueness X% and which another China revenue on of on growth, driven consisted adjusted single-digit this flat during above-market growth strong the organic opportunities. expansion Diagnostics low menu and generated
anniversaried revenue contract business Our completions year. quarter. pressured lab it This driven as organically new the low grew last by in in stabilization has Reproductive business now project which the our Health and delays, was the digits single growth in Omics
Screening Newborn continued digits mid-single to and in perform the Our well globally. quarter the grew in
the continued instrumentation experienced testing Clinical the we into of COVID XXXX expected, and for half in customer year, they spending business absorb in pharma resulting as declining year-over-year. had mid-XXs customers Finally, business continued our the subdued. the in Genomics pressures Applied this our to latter purchased this remains
to and to in performance Genomics decline Applied improve as high progresses, expect our the full the year single-digit for business expect We a we continue the year.
China expectations. decline to quarter, single-digit Reproductive line of which for as by high revenue pertains a specifically, mid-single country with our declined significant it decline was This overall year-over-year, the Immunodiagnostics, Diagnostics high-teens the with As consisted offset Health. in mentioned, in a in digits growth the in our in in
the related lockdowns birth COVID under rates Health more reopening faced incremental impact Reproductive business the headwinds from Chinese Our as the came pressure to ending and wave.
in declined anticipated. slightly China digits, mid-single was Life business than better Our Sciences which we had
to impact not our cautious show While talk have there industry, has assumptions potential been regarding we are additional any stimulus, could point, Consequently, at pertains impact seen this this arise, on to are to capitalize as that up orders. opportunities could our we we business remaining on ready yet which in the our year. this while it
X% growth to results, the includes our regards assumptions, in are In the year outlook maintaining our the full of which QX our organic encouraged X% to by remainder but for year, we range. are
us environment X pharma now assume these end continue. over is softer experienced that months more our leading that from market insights feedback the the are will to constructive, last While we've partners
clear Given to will any potentially how adjustments dynamic the making to remainder things we want our of signs outlook the recovery of have year. for been, see before
to revenue won't our as half a result, the quarter. growth year until second low single we expect company return the the this decline organic As expect second in organic of digits to the we positive in
from now $X.XX anticipate the in currency year, X% tailwind billion. Given expected a billion full year our last the be assumption. to to in to this months, the This increased rates our $X.XX we results revenues fluctuation our range revenue of impact neutral to previous in few over FX have now down
the continue P&L, of expenses. to actions XX% flat return to operating expect are our cost this margins recent down our year roughly hold we Moving some at as the variable offsetting
improving We fourth year average continue third the to second fairly full quarters operating be in similar margins to our the below expect before our in slightly and and sequentially quarter.
we offset each which few Below expect line, now moving a pieces, the largely operating other.
$XX our our now million expenses $XX other down to net be interest for we the year approximately million, First, expect outlook. prior from and
However, be tax a which to expect approximately by this still we to will modestly higher-than-expected rate, round offset XX%.
will count, assume we share XXX.X still million diluted average year. shares be Our this
the we first the year remaining to below-the-line what FX the of our in here largely as adjusted For specifically, unchanged in quarter by similar the the being in just quarter $X.XX we offset first we the quarter. the range items second results now are outperformance to for expect to reported $X.XX in headwinds $X.XX increased is our facing. be guidance have This EPS
first to has cash company We are and a over despite market. a on performed in in executing we have well fully the come. made our When to end managing combined deliver success initiatives the in our differentiated closing, us strong that flow. are did extremely months years challenging across expenses great driving with our the improvements innovation those processes XXXX such to well job on our as positioning several our continued bringing transformation significant more organization key In control, performance of items and both market, the the
we for that, open to With up now call Operator, like questions. would the
